EDNRA and Pulmonary arterial hypertension associated with portal hypertension: A retrospective study comparing the effect of inhaled Iloprost and oral Bosentan, an endothelin-1 receptor antagonist used for three years in patients with POPH has shown that inhaled Iloprsot is significantly inferior to Bosentan in terms of survival, event free survival, exercise capacity and hemodynamics.[41]